La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
100 hedge funds and large institutions have $871M invested in La Jolla Pharmaceutical Company in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 25 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
36% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 25
8% more capital invested
Capital invested by funds: $808M → $871M (+$62.7M)
8% more funds holding
Funds holding: 93 → 100 (+7)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
56% less call options, than puts
Call options by funds: $5.85M | Put options by funds: $13.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$29.8M |
| 2 |
Jennison Associates
New York
|
+$29.6M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$22.5M |
| 4 |
BC
Broadfin Capital
New York
|
+$20.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$66.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.4M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$6.44M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$1.9M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.8M |
LJPC Hedge Fund Activity: Q1 2018 in Review
100 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2018, worth a combined $871M — up 7.8% from $808M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LJPC positions and 14 closed out — a net gain of 8 holders — while 34 added to existing stakes and 25 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $29.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $66.9M sold.
- 100 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2018, up from 93 in Q4 2017.
- Funds reported $871M of La Jolla Pharmaceutical Company stock for Q1 2018, up 7.8% quarter-over-quarter.
- 22 funds opened new La Jolla Pharmaceutical Company positions in Q1 2018 and 14 closed out, a net change of +8 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2018 was Perceptive Advisors, an estimated $29.8M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2018 was Consonance Capital Management, an estimated $66.9M sold.
Based on aggregated 13F filings for Q1 2018.